These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28614914)

  • 1. IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir.
    Zhao K; Yang T; Sun M; Zhang W; An Y; Chen G; Jin L; Shang Q; Song W
    Mol Cells; 2017 Jun; 40(6):418-425. PubMed ID: 28614914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy.
    Papatheodoridis G; Goulis J; Manolakopoulos S; Margariti A; Exarchos X; Kokkonis G; Hadziyiannis E; Papaioannou C; Manesis E; Pectasides D; Akriviadis E
    J Hepatol; 2014 Jan; 60(1):62-8. PubMed ID: 24012614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
    Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
    Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application strategies of serum HBV DNA detection in HBV infection patients: A retrospective study of 5611 specimens.
    Liu C; Wu W; Shang S; Huang E; Xun Z; Lin J; Chen T; Yang B; Chen J; Ou Q
    J Med Virol; 2019 Feb; 91(2):249-257. PubMed ID: 30011350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Association of baseline alanine aminotransferase levels with therapeutic effects of entecavir and interferon-
    Xiao Z; Zhou F; Zhou B; Yang J
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Feb; 39(2):150-155. PubMed ID: 30890501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
    Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
    Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
    Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
    Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients.
    Kurihara M; Tsuge M; Murakami E; Mori N; Ohishi W; Uchida T; Fujino H; Nakahara T; Abe-Chayama H; Kawaoka T; Miki D; Hiramatsu A; Imamura M; Kawakami Y; Aikata H; Ochi H; Zhang Y; Makokha GN; Hayes CN; Chayama K
    Antivir Ther; 2018; 23(3):239-248. PubMed ID: 28933704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy.
    Lin TC; Chiu YC; Chiu HC; Liu WC; Cheng PN; Chen CY; Chang TT; Wu IC
    World J Gastroenterol; 2018 Feb; 24(6):725-736. PubMed ID: 29456411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.
    Song JC; Min BY; Kim JW; Kim JY; Kim YM; Shin CM; Lee SH; Hwang JH; Jeong SH; Kim N; Lee DH
    Korean J Hepatol; 2011 Dec; 17(4):268-73. PubMed ID: 22310791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.
    Seto WK; Lam YF; Fung J; Wong DK; Huang FY; Hung IF; Lai CL; Yuen MF
    J Gastroenterol Hepatol; 2014 May; 29(5):1028-34. PubMed ID: 24325451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.
    Lee HA; Seo YS; Park SW; Park SJ; Kim TH; Suh SJ; Jung YK; Kim JH; An H; Yim HJ; Yeon JE; Byun KS; Um SH
    Clin Mol Hepatol; 2016 Sep; 22(3):382-389. PubMed ID: 27729633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.
    Lee MH; Lee DM; Kim SS; Cheong JY; Cho SW
    J Med Virol; 2011 Jul; 83(7):1178-86. PubMed ID: 21567421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir.
    Willemse SB; Jansen L; de Niet A; Sinnige MJ; Takkenberg RB; Verheij J; Kootstra NA; Reesink HW
    Antiviral Res; 2016 Jul; 131():148-55. PubMed ID: 27155352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
    Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study.
    Jun DW; Kim BI; Cho YK; Kim HJ; Kwon YO; Park SY; Han SY; Baek YH; Jung YJ; Kim HY; Kim W; Heo J; Woo HY; Hwang SG; Rim KS; Choi JY; Bae SH; Lee YS; Lim YS; Cheong JY; Cho SW; Lee BS; Kim SH; Sohn JH; Kim TY; Paik YH; Kim JK; Lee KS
    Clin Mol Hepatol; 2013 Jun; 19(2):165-72. PubMed ID: 23837141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.